clinical trial · NCT05658562
A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
Diffuse Large B-Cell LymphomaMT-2111
brief summary
\[Phase I part\] To investigate the safety, tolerability, and pharmacokinetics of MT-2111 monotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). In addition, the dose to be used in the Phase II part will be confirmed. \[Phase II part\] To evaluate the efficacy of MT-2111 monotherapy in patients with relapsed/refractory DLBCL. In addition, the safety and pharmacokinetics will be investigated.
started
Jan 30, 2023
primary completion
Aug 1, 2028
completion
Aug 1, 2028
last updated
Feb 13, 2026
official title
A Phase I/II Open-Label Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol